The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients: Eur J Ophthalmol

Purpose:Management of Graves’ ophthalmopathy remains challenging. Over the last decade, previous studies have shown promising results for Rituximab in the treatment of Graves’ ophthalmopathy. We present the response of 14 individuals with active moderate-to-severe Graves’ ophthalmopathy to Rituximab...

Full description

Saved in:
Bibliographic Details
Published in:European journal of ophthalmology 2020, Vol.30 (5), p.1008-1013
Main Authors: Eid, L., Coste-Verdier, V., Longueville, E., Ribeiro, E., Nicolescu-Catargi, B., Korobelnik, Jean-François
Format: Article
Language:English
Subjects:
Life Sciences
Santé publique et épidémiologie
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose:Management of Graves’ ophthalmopathy remains challenging. Over the last decade, previous studies have shown promising results for Rituximab in the treatment of Graves’ ophthalmopathy. We present the response of 14 individuals with active moderate-to-severe Graves’ ophthalmopathy to Rituximab, representing one of the largest retrospective case series reported to date.Methods:Rituximab was administered intravenously, 1000 mg twice at a 2-week interval. The primary end point was a clinical activity score reduction (improvement by ⩾ 2 points or disease inactivation: clinical activity score 
ISSN:1120-6721
1724-6016
DOI:10.1177/1120672119845224